Metabolic Optimization and Risk of Metachronous Advanced Colorectal Neoplasia in Patients With MASLD

Is there an association between the dynamic reduction of cardiometabolic risk factors (CMRFs) and lower risk of metachronous advanced colorectal neoplasia (ACRN) among patients with metabolic dysfunction–associated steatotic liver disease (MASLD) after polypectomy? In this cohort study of 2331 patients with MASLD, reducing CMRF counts during follow-up after polypectomy was associated with decreased metachronous ACRN risk compared with no reduction. This decreased risk was more pronounced among high-risk patients with 5 CMRFs or ACRN at baseline. The findings suggest that longitudinal metabolic optimization may be a primary prevention strategy against ACRN in patients with MASLD.

Corresponding Author: Han-Mo Chiu, MD, PhD, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, Taiwan (hanmochiu@ntu.edu.tw).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.